$EVH

Evolent Health (EVH) Misses Q3 Earnings Estimates

Evolent Health (EVH) delivered earnings and revenue surprises of -50.00% and +2.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 6, 2025, 11:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 7, 2025, 2:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Evolent Health (EVH) Misses Q3 Earnings Estimates — source image
Decision brief

The 30-second read

$EVHBearishMed
01

Why it matters

The earnings miss indicates short-term weakness, but the modest revenue growth suggests some resilience. Market reaction may be volatile, especially if investors interpret the miss as a sign of underlying issues.

02

Market read

The news is highly relevant for traders with short-term horizons focusing on healthcare stocks, especially EVH.

03

What to watch

Potential for sector-wide recovery or broader market correction influencing stock movements; macroeconomic factors not considered here.

Timing: short-term (next 1-2 weeks)

Background

Evolent Health reported Q3 earnings that significantly missed expectations, with a -50% surprise in earnings but a slight revenue increase.

Company-level read

Ticker impact

$EVHBearishMedium confidence
Context

Primary focus due to earnings miss

Expected impact

Potential near-term decline of 5-10%, with possible stabilization or rebound if fundamentals improve or market conditions shift.

Evidence & confidence

The large earnings miss is a strong negative signal, but the modest revenue increase and overall market sentiment are mixed. Technical indicators and industry trends should be monitored for confirmation.

Market effects

Potential negative sentiment in healthcare services sector due to earnings miss

Limited; primarily affects US-based healthcare stocks

Low; impact is localized to specific sector and company

Counterpoint

The earnings miss may be an anomaly; if EVH has strong long-term fundamentals, the stock could rebound after an initial dip.

Key entities

  • Evolent Health

    A healthcare technology and services provider.

Related articles

$EVHMed

EVH Q2 2026 Deep Dive: Oncology Suite and AI Automation Drive Growth Amid Membership Headwinds

Evolent Health (EVH) reported Q2 CY2026 revenue of $652.5 million, up 46.9% year on year, beating Wall Street expectations. Full-year revenue guidance of $2.65 billion at the midpoint was 5.9% above analysts’ estimates. Non-GAAP EPS was $0.02. Management cited Highmark contract launch, renewals, and scaling of its Auth Intelligence AI automation, while noting Medicaid and exchange membership headwinds.

$EVHMedAI 8/10

Why is Evolent Health stock surging today?

Evolent Health (EVH) shares rose 23.4% in pre-market after the company reported Q2 2026 results. According to the article, EPS was $0.02 versus -$0.01 expected, and revenue was $652.52M versus $597.46M expected, up about 47% year over year. The move was linked to short interest with days to cover near 5.67 and multiple EPS estimate revisions.

$EVHMedAI 8/10

Evolent Announces Second Quarter 2026 Results

Evolent Health (NYSE: EVH) reported Q2 2026 results for the three months ended June 30, 2026 and raised 2026 revenue guidance to $2.6 to $2.7 billion and Adjusted EBITDA to $120 to $135 million. The company expects 2027 revenue growth of over 25% and Adjusted EBITDA midpoint at or above $150 million. It also outlined two partnership updates, including a $300 million annualized oncology deal.

$EVHHigh

Evolent Health, Inc. (EVH): Results of Operations and Financial Condition

Evolent Health, Inc. (EVH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2exhibit991.htm EX-99.1 Document Exhibit 99.1 Evolent Announces Second Quarter 2026 Results WASHINGTON (August 6, 2026) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex co

$NVDAMed

Nvidia to Invest Up to $3 Billion in Blackstone

The Information reported Nvidia plans to invest up to $3 billion in Lancium, a Blackstone-backed power and data center infrastructure developer tied to the Stargate AI initiative. Nvidia would initially put in $2 billion for a 20% stake, with up to $1 billion more contingent on performance thresholds. No company comment was provided.